The Pill that
moves the needle®
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform.
We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise.
Our Mission
From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases.
We are dedicated to advancing vaccine science to create safe, effective, and accessible solutions that protect communities worldwide and empower people to lead healthier lives.
Our Science
Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology.
VAXART News
-
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
-
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
-
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
See News and SEC Filings for additional important information.